Table 2. Influence of EGFR status (gene copy number) on subject response in KRAS wild-type MCRC patients treated with anti-EGFR mAb-based CT.
|
PFS (months)
|
OS (months)
|
Responders | Nonresponders | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | N | EGFR cutoff | No | 95% CI | P-value | No | 95% CI | P-value | CR+PR | SD+PD | P-value |
| Moroni et al (2005) | 20 | ⩾3a | — | — | 6 | 1 | 0.001 | ||||
| <3 | — | — | 1 | 12 | |||||||
| Personeni et al (2008) | 58 | ⩾2.83a | 5.5 | 0.25 | 10 | 0.037 | 17 | 10 | 0.007 | ||
| <2.83 | 4 | 8.3 | 8 | 23 | |||||||
| Laurent-Puig et al (2009) | 116 | ⩾2a | 8.5 | 7–16 | 0.28 | 20 | 13–NA | 0.018 | 12 | 5 | 0.015 |
| <2 | 7 | 5–8.5 | 14 | 11–17 | 29 | 50 | |||||
| Scartozzi et al (2009) | 44 | ⩾2.6a | 7.7 | 0.04 | 16 | 0.2 | 9 | 6 | 0.001 | ||
| <2.6 | 2.9 | 9.5 | 2 | 21 | |||||||
| ⩾2.12b | 6.4 | 0.02 | 10.6 | 0.95 | 10 | 18 | 0.04 | ||||
| <2.12 | 3.1 | 10.3 | 1 | 15 | |||||||
| Tol et al (2010) | 155 | ⩾3a | 9.5 | 6.4–12.3 | 0.19 | 21.9 | 13.4–27.1 | 0.65 | — | — | |
| <3 | 10.4 | 8.6–12.2 | 22 | 19.2–25.4 | — | — | |||||
Abbreviations: CI=confidence interval; CISH=chromogenic in situ hybridisation; CR=complete response; CT=chemotherapy; EGFR=epidermal growth factor receptor; FISH=fluorescence in situ hybridisation; mAb=monoclonal antibody; MCRC=metastatic colorectal cancer; NA=not assessable; OS=overall survival; PFS=progression-free survival; PR=partial response; PD=progressive disease; SD=stable disease.
a
FISH.
b
CISH.